-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
1/19
Nigerian Healthcare & PharmaceuticalsSector Update
January 2011
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
2/19
Healthcare/Pharmaceuticals Sector
Healthcare in Nigeria The provision of healthcare in Nigeria is the responsibility of all three tiers
of government. The federal government's role is centered primarily around
the formulation and implementation of broad healthcare policy as well as
the management of teaching hospitals (tertiary healthcare). The state
governments manage various general hospitals (secondary healthcare)
while local governments are tasked with the provision of primary
healthcare services in the form of dispensaries and clinics. Nigerias
pharmaceuticals sector is regulated by the National Agency for Food and
Drug Administration and Control (NAFDAC).
In the last five decades, the Nigerian health sector has remained grossly
underdeveloped, despite seeming better off than other African peers.
Healthcare delivery in Nigeria is characterized by inefficient budget
execution, inadequate funding, poor service quality and a shortage of
qualified personnel essential to the delivery of public health services.
Despite modest increases in healthcare budgetary allocation,
improvements to key health indicators have been rather limited. Nigerias
health indices remain amongst the poorest in the world. As of 2009, life
expectancy was estimated at 47.7 years, while infant mortality rate was 75
per 1000 live births. The countrys maternal mortality rate deteriorated
from 800 to 1,100 per 100,000 live births between 2000 and 2010. High
infant and child mortality/morbidity rates are the effects of poor
sanitation, low income and other determinants of poverty through theoccurrence of infectious diseases such as malaria, HIV/AIDs, TB, diarrhoea
and cholera. Poverty is widespread with over 70.0% of the population
living below the poverty line, with an ever widening gap between the rich
and the poor.
The absence of effective methods of addressing the healthcare needs of
the poor and underserved populations (mainly in rural areas) as well as the
low levels of government expenditure (currently averaging 5.4% of the
total budget since 2008) have contributed to the nations dismal health
statistics. Other indicators show that only about 10.0% of Nigerians have
access to essential drugs, with a workforce estimated at 4 physicians to
every 10,000 people. Worse still, the level of healthcare for such chronic
conditions as hypertension, diabetes and arthritis prevalent in ageing
populations is grossly insufficient.
1
Nigerian Healthcare & Pharmaceuticals SectorUpdate
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
3/19
Healthcare/Pharmaceuticals Sector
Chart 3: 2010 Life Expectancy at Birth Nigeria vs Others Chart 4: 2010 Life Expectancy at Birth Developed Countries
Source: WHO, Afrinvest Research
8174
81 80 83
68
80 78
0
10
20
30
40
50
60
70
80
90
Can
ada
China
Fra
nce
Germ
any
Japan
Ru
ssia
UK
USA
Source: WHO, Afrinvest Research
47 4951 53
55 5760
6469 71
7379
0
10
20
30
40
50
60
70
80
90
Nigeria
CAR
Cameroon
C
ongo
South
Africa
Kenya
G
hana
India
Algeria
Mo
rocco
Brazil
Chile
2
Chart 1: 1990 Life Expectancy at Birth Nigeria vs. Others
Source: WHO, Afrinvest Research
4651
55 58 5860 60 63
65 66 6772
0
10
20
3040
50
60
70
80
Nigeria
CAR
Cameroon
Ghana
India
Congo
Kenya
South
Africa
Morocco
Algeria
Brazil
Chile
Source: WHO, Afrinvest Research
77
68
77
75
79
69
7675
62
64
66
68
70
72
74
76
78
80
Canada
China
France
Germany
Japan
Russia
UK
USA
Chart 2: 1990 Life Expectancy at Birth Developed Countries
Years Years
Years Years
3 4 6 8 1121 22
67 6976
128144
186
0
40
80
120
160
200
Japan
France
UK
USA
Russia
China
Brazil
SouthAfrica
India
Ghana
Kenya
Liberia
Nigeria
Chart 5: Estimated Under 5 Mortality Rate in 2008
Source: WHO, Afrinvest Research
3 3 5 59
18 18
48 51 52
81
96 100
0
2040
60
80
100
120
Japan
France
UK
USA
Russia
China
Brazil
SouthAfrica
Ghana
India
Kenya
Nigeria
Liberia
Chart 6: Infant mortality rate Per 1000 Live Births 2008
Source: WHO, Afrinvest Research
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
4/19
Healthcare/Pharmaceuticals Sector
Malaria is a major health problem in Nigeria, as the country accounts for as
much as a quarter of the total malaria burden in Africa. Malaria is
responsible for about 60.0% of all clinic attendances and accounts for
approximately 20.0% of childhood mortality and 11.0% of maternalmortality cases in Nigeria. The key challenges facing malaria control
include inadequate provision of anti-malaria drugs and the use of
preventive measures such as insecticide-treated nets, a dearth of technical
skills/competence, infrastructure for managing the storage and distribution
of large quantities of medicines, insufficient human capital, high cost of
service delivery at sub-national levels, lack of proper/efficient
management structures and capacity at state and local government levels
and inadequate funding. There have however been renewed efforts aimed
at controlling malaria such as the targeted use of Artemisinin-based
Combination Therapies (ACTs, a more effective treatment), encouraging
the widespread use of insecticidal nets and indoor residual insecticide
sprays to combat the vector, mosquitoes.
Estimates by the Federal Ministry of Health indicate that approximately 3.0
million people were living with HIV/AIDS in Nigeria in 2009, with a total of
192,000 deaths attributed to the disease. One of the most significant social
and economic impacts of HIV/AIDS is the ever increasing number of AIDS
orphans, which was estimated at 2.1million in 2008 and 2.2million in 2009.The Nigerian government has however shown considerable commitment to
the fight against HIV/AIDS. Through the HIV/AIDS governing body, the
National Agency for the Control of Aids (NACA), government has
articulated policies which influence every area of the nations response to
the HIV/AIDS scourge. The revised HIV/AIDS policy is a result of broad
consultations with various relevant stakeholders such as civil society
organizations, government ministries and parastatals, development
partners, donor agencies and community based organizations.
The National Health Policy emphasizes the importance of adequate health
care to social and economic development and acknowledges primary
healthcare as the foundation of Nigerias healthcare system. Over the last
few years, there has been an increase in government spending directed
towards providing new facilities mainly at the primary healthcare level.
Nigerias Disease Burden
HIV/AIDS
Malaria
3
Cholera
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
5/19
Healthcare/Pharmaceuticals Sector
Over the years, Nigeria has maintained a high incidence of Wild Poliovirus
(WPV) cases due to persistently low levels of immunization in children. In
2008, Nigeria reported 798 polio cases, the highest number in the world.
Reported polio cases however decreased to 388 in 2009 (24% of global
cases), reaching an all-time low during the first half of 2010, with onlythree reported cases. In 2009 - 2010, the increased involvement of
traditional, religious and political leaders aided the acceptance of
vaccination and implementation of high-quality supplementary
immunization activity. In June 2010, the Centers for Disease Control and
Prevention reported a significant drop in polio cases in Nigeria. Improved
poliovirus surveillance and immediate immunization responses to new
cases are critical factors in bringing an end to the occurrence of the virus.
According to the WHO 2010 World Health Statistics Report, the number of
incidences of TB fell marginally from 311 to 300 cases per 100,000 persons
between 2007 and 2008. Nigeria, a country of about 150.0 million people,
ranks amongst the top 5 of 22 countries with the highest incidences of TB
with some 100,000 recorded deaths annually. An analysis of the
distribution pattern of TB reveals a high level of concentration around
densely populated communities, with Lagos having the highest number of
recorded cases in the country. Major challenges to the reduction of the TB
burden include human resource constraints, poor coordination of various
efforts, ineffective resource management and existing significant funding
gaps.
Tuberculosis
4
Polio
19%
0%
20%
16%
8%
8%
6%
2%
17%
1%3%
HIV/AIDS
Diarrhoea
Measles
Malaria
Pneumonia
Prematurity
Birth asphyxia
Neonatal sepsis
Congenital abnormalities
Other diseases
Injuries
Chart 7: Distribution of Causes of Death in Children < 5 years in Nigeria 2008
Source: WHO, Afrinvest Research
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
6/19
Healthcare/Pharmaceuticals Sector
The National Health Policy emphasizes the importance of adequate health
care to social and economic development and acknowledges primary
healthcare as the foundation of Nigerias healthcare system. Over the last
few years, there has been an increase in government spending directed
towards providing new facilities mainly at the primary healthcare level.However, most health facilities still lack modern medical equipment.
Healthcare facilities are often staffed by a few highly skilled often
inadequately remunerated professionals and endure frequent drug
scarcities resulting in the continued dependence on secondary and tertiary
health care institutions. In spite of the fact that government-funded
primary health care facilities constitute the vast majority of medical
facilities in Nigeria, the private sector still provides most of the secondary
healthcare services while most Nigerians continue to depend on outof
pocket expenditure for meeting their healthcare needs.
According to the WHO 2010 statistics report, the total expenditure on
health care as a percentage of GDP was 6.6% in 2007, up from 4.6% in
2000. Despite the country's profile as one of the worlds developing
economies, over a decade of sustained democratic governance and the
governments economic reforms, the health care sector remains critically
underdeveloped and continues to suffer neglect, while other sectors such
as defence, oil and gas, Niger Delta and security have received better
government attention. In contrast, the governments of Ghana and South
Africa allocated over 10.0% of their total annual expenditure to their
healthcare sectors.
5
Funding
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
7/19
Healthcare/Pharmaceuticals Sector
There have been several attempts at reforming the health sector in Nigeria,
centered around developing institutional capacity and accessibility to
public health services. One of the more notable initiatives aimed at
addressing the issue of qualitative healthcare delivery was the creation of
the National Health Insurance Scheme (NHIS). The NHIS was signed into law
in May 1999 by the Obasanjo administration but actually took off in 2005.
It was aimed at complementing sources of financing for the health sector
and improving access to health care for the majority of Nigerians.
The NHIS was designed to mirror practices of health insurance schemes in
more developed countries such as the United States of America and the
United Kingdom. Its objectives upon inception were to:
Ensure that all Nigerians have access to quality healthcare services and
protect families from colossal medical bills;
Ensure impartial distribution of healthcare costs among different social
strata;
Sustain a high standard of healthcare delivery;
Ensure efficiency in healthcare services;
Improve and harness private sector participation in the provision of
healthcare services;
6
35.0
16.8 18.5
78.6
6.3
27.7
40.0
12.6
47.2
3.6
30.8
0
10
20
30
40
50
60
70
80
90
Power
Tran
sport
H
ealth
Agriculture
W
ater
Reso
urces
Education
Works
Niger
Delta
FCTA
PoliceA
ffairs
TotalBudget
Average
Chart 8: HY 2010 Budget Implementation Various Sectors
Source: Federal Ministry Of Finance
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
8/19
Healthcare/Pharmaceuticals Sector
Ensure adequate distribution of health facilities within the Federation;
Ensure the availability of funds to the health sector for improved
services.
Despite its noble intentions, limited progress has been made regarding the
adoption of the scheme which, for the most part, remains limited to public
sector employees. As most Nigerians still depend on out-of-pocket
spending for meeting their healthcare needs, there are concerns regarding
the governments ability to manage such complex schemes, given its track
record on other similar public schemes, such as the National Housing Fund.
In retrospect, Afrinvest Research is of the opinion that the original goals of
the NHIS may have been somewhat ambitious, given the current state of
the countrys primary healthcare system. This is due to the lack of a
comprehensive approach to the formulation and implementation of
healthcare administration to aid the development rather than the
adoption of a system of primary health care.
7
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
9/19
Healthcare/Pharmaceuticals Sector
The pharmaceutical industry in Nigeria began in 1957 with the
establishment of the first pharmacy in Lagos. At the time, the
pharmaceuticals business primarily involved the distribution of drugs by
representatives of different multinational drug manufacturing companiespresent in Nigeria such as Beecham, May & Baker, Pfizer and Glaxo. This
was followed by the establishment of manufacturing plants by some of
these multinationals who thereafter scaled up their operations following
the end of the Nigeria-Biafra civil war and the onset of the oil boom in the
early 1970s. These companies were completely owned and controlled by
foreigners, with no indigenous participation. The indigenization policy of
1978 ushered in the next phase of development in the industry, forcing the
multinational companies into selling a minimum 60.0% equity stake to
Nigerians. This was followed by the establishment of indigenous
pharmaceutical manufacturing companies both by individuals and the
government. Between 1980 and 1982, there was an increase in the local
production of drugs from 5.0% to 20.0% of total demand, thereby
impacting economic growth positively and presenting many individuals
with investment opportunities.
The chronic dependence on importation of finished goods, following the
oil boom, had a catastrophic effect on the economy and ultimately the
pharmaceutical industry. The introduction of the notorious import licenses(which covered drug imports) also impacted the industry negatively as
these licenses were not issued based on merit or technical competence. This
resulted in the sidelining of genuine manufacturers, importers and
pharmacists who then had to repurchase these licenses (often at a
premium). As a result, the Nigerian market was flooded with fake,
counterfeit and substandard drugs. During this period however, there was
an increase in the number of indigenous manufacturers though local
capacity for the production of the most basic of raw materials for
manufacturing pharmaceuticals remained grossly underdeveloped. In morerecent times, there has been a measure of respite in the industry due to;
the amendment of the Essential Drugs List (EDL) Decree, the abolition of
the import licensing system and Value Added Tax (VAT) on pharmaceutical
products, in addition to the reduction of tariffs on raw materials.
Furthermore, the unrelenting campaign by NAFDAC in the war against
counterfeit, fake and substandard drugs has greatly impacted the industry.
8
Nigerias Pharmaceuticals Sector
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
10/19
Healthcare/Pharmaceuticals Sector
The sector can be classified based on product type, as well as by
manufacturer location (local manufacturers versus foreign importers).
Over-the-Counter (OTC) drugs are easier to manufacture and account for
larger volumes albeit, with thinner margins in a more competitive market
space. Ethicals on the other hand are, in most cases, products of years ofResearch and Development (R&D) and are estimated to have only a 20.0%
market share of the Nigerian market but with much wider margins. Large
multinational corporations currently dominate the ethicals segment of the
market. Imported drugs however account for an estimated 65.0% of
market size. According to data from the Pharmaceuticals Manufacturers
Group of the Manufacturers Association of Nigeria (PMG-MAN), the local
market of pharmaceutical producers (accounting for an estimated 35.0% of
market size) is a highly fragmented one. The industry consists of 128
registered local pharmaceutical manufacturing companies, 292 registered
importers, 724 registered distributors, as well as a large number of
unregulated manufacturing, importing and distribution businesses. The
size of this unregulated market is difficult to accurately quantify as these
operators do not make returns to industry associations or regulatory
bodies.
The Nigerian pharmaceuticals sector has consistently been underutilized
(from a capacity perspective) over the past few decades as a result of
widespread counterfeiting, infrastructural challenges and corruption,
despite evident demand for effective drugs. In spite of the substantial
growth potential within the pharmaceutical and healthcare industry, the
elements of risk and uncertainty that currently subsist, limit international
interest/investment in the sector. The government has demonstrated its
willingness to make the country self-sufficient in terms of drug
production, by restricting imports through partial regulatory regimes and
tackling counterfeits.
There are 2 main layers in the production of pharmaceutical products in
Nigeria. These include (i. manufacturing and ii. packaging/repackaging) of
drugs, predominantly done by multi-nationals and a few indigenous drug
companies. These multinational organizations are also involved in the
wholesale distribution of pharmaceuticals, while the indigenous
wholesalers and retailers concentrate on sales to consumers. The retailers
mainly consist of pharmacies and patent medicine stores that dispense
both over-the-counter as well as prescription drugs, amongst others.
9
Overview
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
11/19
Healthcare/Pharmaceuticals Sector
It is important to note that most of the companies in the
pharmaceuticals sector function primarily as importers, distributors or
retailers for international brands. By extension, Nigerias health services fall
under the control of Western countries (Britain, USA and France) as well as
some Asian countries (India, China and Indonesia). This could have seriousimplications as economic and socio-political developments in these
countries could directly or indirectly impact prices, availability and
affordability of drugs for Nigerian consumers. The Nigerian pharmaceutical
industry is made up of 86 local manufacturers who collectively produce less
than 30.0% of Nigerias pharmaceutical needs. A major reason for the
underutilization of local pharmaceutical capacity is the increased
competition by imported products from countries such as China and India.
Access to essential medicines is fundamental to the realization of the
Millennium Development Goals (MDGs). Despite governments noble
intentions, poor availability, high cost and irrational use of essential
medicines continue to plague the pharmaceuticals sector. Efficient
provision of essential drugs depends on appropriate selection,
quantification, procurement, quality and storage, distribution, human
resources and information management.
Reports indicate an uncoordinated approach to the management of drugs
between various stakeholders, especially the government and aid
organizations. This has resulted in the poor management and procurement
of drugs by the Ministry of Health as it makes use of inadequate
procedures in the selection of drugs, despite the awareness of the national
Essential Drugs List (EDL). This lack of synergy between the governments
procurement procedures and the efficient use of the EDL in meeting the
actual pharmaceutical needs of the country has led to the overstocking of
certain drugs. Bulk procurement of drugs without proper negotiation,
geared towards optimizing the benefits of economies of scale, has also led
to higher costs of drugs relative to other countries. Drugs are also procured
without having mapped out effective distribution plans, thus resulting in
the delivery of drugs with short shelf lives.
10
Overview
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
12/19
Healthcare/Pharmaceuticals Sector
Nigerias pharmaceutical market is considered one of the smallest in the
Middle East and African region. It is dominated by a few large
organizations predominantly involved in the importation and distribution
of internationally recognized brands, production and distribution of
consumer goods and consumer health products. Most domesticpharmaceutical companies and health care providers find it extremely
difficult to compete internationally which is evident in their generally low
levels of investment in research and development. Reasons for their
inability to compete include; inadequate government funding, low drug
expenditure, poor infrastructural development, insufficient facilities to
meet the demand for health care, the absence of an adequate regulatory
environment, insufficient foreign investment due to low confidence on
growth prospects, dearth of professional and technical competence in the
research and formulation of complex drugs. High levels of inequality
within the social system also play a part as low income earners are the
highest users of medical and pharmaceutical care. There is also a high level
competition from low-cost generic drug producers in the emerging Asia
markets and the prevalence of fake and counterfeit drugs especially in the
rural areas.
The makeup of Nigerias disease burden should provide economic
opportunities within the market in the areas of Antiretroviral (ARVs),
Artemisinin-based Combination Therapy (ACT) and vaccines in the
continuous battle against HIV/AIDS, Malaria, TB and Polio. However, the
current health profile of the country suggests a huge, though largely
unmet, demand for drugs and medical care. This in turn presents various
opportunities for the development of the market and individual producers
providing a large customer base. The federal governments restructuring of
NAFDAC in view of its past successes has moderately improved
confidence in the sectors reform. NAFDACs determined efforts at
reducing the prevalence of counterfeit and substandard drugs has
recorded some levels of success, with the agency being regarded as one ofthe most effective and influential government agencies since Nigeria
returned to civilian rule. Governments increased awareness and budgetary
allocations should have a positive effect on the industry, as it aims to
achieve its 4th and 5th Millennium Development Goals which are to reduce
child mortality rate among children and reduce maternal mortality rate by
75.0% by the year 2015.
11
Stunted Growth
Opportunities
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
13/19
Healthcare/Pharmaceuticals Sector
Since its inception in 2002, Nigeria has been granted approximately
US$500.0 million by the Global Fund (a multilateral financing organization
for health with a focus on Malaria, HIV/AIDS and TB) and has recently
made a voluntarily contribution to the fund to the tune of US$10.0 million,
bringing its total contributions to US$30.0 million. The organizationsAffordable Medicine Facility-malaria (AMFm) scheme aims to slash the
price of Artemesinin-based Combination Therapies (ACTs) by providing
large quantities of highly subsidized ACTs. This poses a considerable risk for
local manufacturers as none of the locally produced ACTs has been selected
to be part of this 2 year program in which up to 95.0% of the costs of these
drugs will be subsidized. The supposed local companies that have been
selected are actually multinational entities who have established
companies within the country. The absence of indigenously manufactured
ACTs on the list of accepted drugs underscores the inability of the domestic
pharmaceutical industry to compete internationally. The main reason
behind the non-inclusion of locally manufactured ACTs in the scheme is
down to their exclusion from the WHO list of pre-qualified drugs despite
the fact that some of these medications have been certified by the same
organization.
Afrinvest Researchs coverage of the pharmaceuticals industry is based on
production capacity, asset base and market capitalization of the listed
equities on the Nigerian Stock Exchange. In our view, the key listed players
in this market space are GlaxoSmithKline (GSK), May & Baker and Fidson
Healthcare (a fairly new addition to the listed healthcare companies). Most
companies within the sector achieved negative sales growth in 2009,
cascading down to dismal bottom line numbers with few exceptions (GSK
and Fidson). This is largely due to unsuccessful forays into the
consumer goods market and inadequate working capital management as a
result of funding gaps necessary for capacity upgrades in addition to the
difficult operating conditions. Overall, the sectors growth has been limited
(Afrinvest Research estimates 2.6% in 2009), with a few players chasing the
expensive and difficult to attain WHO pre-qualification, putting pressure
on working capital positions.
Further analysis of the balance sheet of these companies reveals that
majority of the sector participants are considerably leveraged, with a large
dependence on short term funding without significant capital raising
activity throughout the year.
12
Unhealthy Competition
Sector Performance & Outlook
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
14/19
Healthcare/Pharmaceuticals Sector
An analysis of operating and valuation statistics remains less than
encouraging, reflecting our view on the state of the countrys healthcare
industry despite huge market opportunities. In comparison to 2009, the
sector performed considerably better on the NSE in 2010 appreciating by
19.1% in 2010 relative to 18.9% increase in the NSE All Share Index (NSEASI). This was largely due to the price appreciation movements in May &
Baker, Fidson and GSK by 52.3%, 71.9% and 16.1% respectively.
13
80.0
90.0
100.0
110.0
120.0
130.0
140.0
Jan-10
Feb-10
Mar-10
Apr-10
May-10
Jun-10
Jul-10
Aug-10
Sep-10
Oct-10
Nov-10
Dec-10
Sector
NSE ASI
Chart 9: 2010 Performance of Healthcare Companies Chart 10: NSE ASI vs. Healthcare/Pharmaceutical Sector 2010
Source: Afrinvest Research, NSE Source: Afrinvest Research, NSE
Rebased. Jan 04, 2010=100
71.9
52.3
19.1
18.9
16.1
2.8
-4.8
-13.9
-14.2
-18.0
-29.3
-40.0 -20.0 0.0 20.0 40.0 60.0 80.0
Fidson
May & Baker
Sector
NSE ASI
GSK
Evans
Ekocorp
Pharma-Deko
Morison
Union Diagnostic
Neimeth
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
15/19
Healthcare/Pharmaceuticals Sector14
Price TSO (MM) Market Cap EV EBITDA FYA EBITDA 1YF
CompanyLatest Audited
Accounts
31-Dec-10 Ordinary (Naira) (Naira) (Naira) (Naira)
Fidson 30-Jun-09 3.06 1,500.0 4,800.0 4,985.4 937.2 1,003.8
GSK 31-Dec-09 26.00 956.7 24,874.3 22,724.9 2,984.7 3,810.4
Neimeth 31-Mar-10 1.06 821.6 870.9 1,010.9 (218.0) 305.2
May & Baker 31-Dec-09 4.20 980.0 4,116.0 4,194.2 643.4 660.9
Evans 31-Dec-08 1.10 486.5 535.1 1,432.4 113.5 363.6
Source: Afrinvest Research, NSE, Company Annual Accounts
EPS EV/Sales EV/EBITDA Price / Book Value P/E
Company FYA 1YR E FYA 1 YR F FYA 1 YR F FYA 1 YR F Trailing 1 YR F
Fidson 0.29 0.36 1.0x 0.9x 5.3x 5.0x 1.0x 0.9x 11.2x 8.8x
GSK 1.78 2.34 1.5x 1.3x 7.6x 6.0x 3.5x 2.9x 14.6x 11.1x
Neimeth (0.55) 0.19 0.5x 0.5x N/M 3.3x 0.9x 0.8x N/M 5.5x
May & Baker 0.33 0.71 0.9x 0.9x 6.5x 3.5x 1.6x 1.2x 12.7x 5.9x
Evans (1.05) (0.08) 0.3x 0.3x 12.6x 3.9x 1.7x 1.8x N/M N/M
Mean 1.0x 0.9x 6.5x 4.4x 1.7x 1.5x 12.8x 8.6x
Median 1.0x 0.9x 5.9x 4.2x 1.3x 1.1x 11.9x 7.4x
Source: Afrinvest Research, NSE, Company Annual Accounts
Table 1: Trading & Valuation Statistics Healthcare /Pharmaceuticals Sector, (Naira in MM, Except Where Noted)
Table 2: Trading & Valuation Statistics Healthcare /Pharmaceuticals Sector
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
16/19
Healthcare/Pharmaceuticals Sector
0.0
50.0
100.0
150.0
200.0
250.0
Jan-10
Feb-10
Mar-10
Apr-10
May-10
Jun-10
Jul-10
Aug-10
Sep-10
Oct-10
Nov-10
Dec-10
Sector
NSE ASI
Fidson
New Kid On The Block
Fidson Healthcare Plc commenced operations in 2002 and was listed on the Nigerian Stock
Exchange in June 2008. The company is parent to Fidson Products Limited (FPL), a wholly
owned subsidiary and a conduit for the companys diversification into the consumer goods
market. FPL produces a handful of unique consumer goods such as absorbent materials,
tissues, diapers and hair removal cream. The companys pharmaceutical product range
includes antibiotics, vitamin supplements, generics, ACTs, ARTs antidepressants and
dermatological creams.
Just Above Par
In 2009, there was a decrease in the companys bio-science and generics business lines, while
receiving increased contributions from their specialties and general goods businesses. Fidsons
performance in 2009 was encouraging (given the difficult operating environment), growing
sales by 11.5% and increasing EBITDA by 6.9%. In 2009, EBITDA and EBIT margins were
consistent at 18.7% and 16.2% respectively, above the industry average. However, in its more
recently published Q3 March 2010 results, there was a reduction in sales (-1.4%) with a
marginal 1.3% growth in earnings. Margins remained consistent at 13.7% and 9.3% (pre and
post tax), implying successful cost control measures, although we believe sales growth during
the period was restricted due to ineffective marketing and distribution strategies.
We Remain Overweight on Fidson
The companys share price performance was impressive last year (YTD 71.9% to 31st December
2010) owing to its more favorable trading liquidity than some sector peers. Based on a trailing
and forward P/E of 10.1x and 9.1x and EV/EBITDA of 4.8x and 4.9x, we expect its share price to
settle around the N3.89 mark in twelve months, implying a 34.0% potential upside to its
current trading price. While we await its FY 2010 results, we are optimistic on Fidson, in light
of recent plans to setup the countrys first Biotech facility, supported by its own range of
consumer healthcare brands, generics, anti-malarial prescriptions, ARVs and Nigerias huge
healthcare demands.
Chart 11: Fidson Healthcare Versus Sector and NSE (LTM Price Performance)
Source: Afrinvest Research
Market Data
Price Range (Low/High) 1.86 - 3.70
Price Performance % (YTD) 71.9
Share Price (Dec 31, 2010) 3.06
Shares Outstanding (m) 1,500.0
Market Cap (Nm) 4,590.0
Market Cap (US$m) 30.6
Avg Daily Value (Nm) 3.9
Avg Daily Value (US$'m) 0.03
Avg Daily Vol (Nm) 1.4
Adjusted Prices, Rebased. Jan 04, 2010=100
Year Ended, June 30 2009 2010F
Sales (Nm) 5,019.8 5,270.8
Profit After Tax (Nm) 429.1 486.2
Earnings per Share (Kobo) 0.29 0.32
Dividend per Share (Kobo) 0.22 0.24
Sales Growth (%) 11.5 5.0
PAT Growth (%) 126.7 13.3
ROE (%) 1.9 2.0
Dividend Yield (%) 9.9 11.0
Company Data
Valuations
EV/Sales (x) 0.9
EV/EBIT (x) 6.1
EV/EBITDA (x) 5.0
Working Capital/Sales (%) 36.4
Capex/EBITDA (%) 126.9
DCF Value (N) 2.41
Fidson Healthcare Nigeria Plc
15
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
17/19
Healthcare/Pharmaceuticals Sector
80.0
90.0
100.0
110.0
120.0
130.0
140.0
150.0
Jan-10
Feb-10
Mar-10
Apr-10
May-10
Jun-10
Jul-10
Aug-10
Sep-10
Oct-10
Nov-10
Dec-10
Sector
NSE ASI
GSK
Leading the Pack..
GSK remains Nigerias largest manufacturer of consumer healthcare and pharmaceutical
products and has been operating in the country since 1972 prior to its listing on the NSE in
1977. GSK is the result of a merger between SmithKline Beecham Limited and Glaxo Wellcome
in 2000. The company has a strong market presence and well established pharmaceutical and
consumer healthcare brands such as Panadol, Ribena, lucozade, Macleans, Ampiclox, Amoxil
and Halfan.
..with Consistent Earnings Growth.
GSKs performance in 2009 reaffirmed its position as the market leader, growing sales and
earnings (EBITDA) substantially (considering the tough economic conditions) by 19.2% and
29.7% respectively. Similarly, margins for the period under review also improved, as both EBIT
and EBITDA margins increased to 16.6% and 20.1% respectively from 14.8% and 18.3% in
2008. There has been consistent growth in top line to Q3 September 2010 as a result of
increased marketing and distribution efforts. The introduction of new products to its
consumer health and pharmaceutical portfolio has also helped in fortifying its brand strength
and consolidating its market share. The most recent quarterly earnings results for Q3 2010
show an improved performance in comparison to the equivalent period in 2009. Sales grew by
12.6% while profits increased marginally by 1.2%, although pre-tax margins declined from
21.0% to 18.9%.
Expected to Maintain Sector Dominance.
GSK trades at trailing P/E of 16.0 times and at a discount to our DCF value estimate of N29.89.
Based on a forward P/E of 11.6x and EV/EBITDA 6.4x, we estimate a 12 month price target of
N34.00, representing an 18.5% upside potential and maintain our BUY recommendation on
the stock. Going forward we believe GSK will continue to dominate the sector by taking
advantage of financial, technical, technological, scientific and professional assistance from
GSK worldwide. We are positive on the companys future earnings potential and believe its
dividend payment will be sustained to FY 10.
Chart 12: GSK Versus Sector and NSE (LTM Price Performance)
Source: Afrinvest Research
Adjusted Prices, Rebased. Jan 04, 2010=100
GlaxoSmithKline Consumer Nigeria Plc
Market Data
Price Range (Low/High) 20.85 - 31.50
Price Performance % (YTD) 16.1
Share Price (Dec 31, 2010) 26.00
Shares Outstanding (m) 956.7
Market Cap (Nm) 24,874.2
Market Cap (US$m) 165.8
Avg Daily Value (Nm) 7.3
Avg Daily Value (US$'m) 0.05
Avg Daily Vol (Nm) 0.3
Valuations
EV/Sales (x) 1.5
EV/EBIT (x) 9.2
EV/EBITDA (x) 7.6
Working Capital/Sales (%) 17.8
Capex/EBITDA (%) 47.2
DCF Value (N) 29.18
Company Data
Year Ended, June 30 2009 2010F
Sales (Nm) 14,952.4 17,174.9
Profit After Tax (Nm) 1,701.8 2,240.7
Earnings per Share (Kobo) 1.78 2.34
Dividend per Share (Kobo) 0.75 1.05
Sales Growth (%) 19.2 14.9
PAT Growth (%) 33.2 31.7
ROE (%) 25.9 28.7
Dividend Yield (%) 2.63 3.70
16
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
18/19
Healthcare/Pharmaceuticals Sector
0.0
50.0
100.0
150.0
200.0
250.0
300.0
Jan-10
Feb-10
Mar-10
Apr-10
May-10
Jun-10
Jul-10
Aug-10
Sep-10
Oct-10
Nov-10
Dec-10
Sector
NSE ASI
MAY & BAKER
First on the scene..
May & Baker is the oldest pharmaceutical manufacturer in Nigeria, founded in 1944 as a
trading outpost for May & Baker Limited UK. The company manufactures and distributes
pharmaceuticals and vaccines and consumer products. The company began an expansion
strategy which commenced with the development of its own branded products, followed by
the introduction of Lily table water and Mimee Noodles. This was supported by its acquisition
of 51.0% stake in Biovaccines Nigeria limited in partnership with the federal government.
Wading Through Muddy Waters
Over the past 5 years, May & Baker has achieved a steady growth of 23.2% (CAGR). In 2009,
the companys sales dropped by 15.0% as a result of negative contributions from its poor
performing food lines and public sector operations. In addition, EBIT & EBITDA also decreased
by 7.0% and 3.6% despite some improvement in margins. Further analysis raises concerns over
the firms debt and working capital positions which have been exacerbated due to efforts to
complete construction of a WHO prequalified production plant, while attempting to revive its
agreement with the federal government over Biovaccines.
Cautious Optimism
Based on the companys performance up to Q3 10, we express concerns on the companys
outlook as the it currently trades at a premium of 14.8% to our intrinsic valuation of N3.66.
We remain cautiously optimistic on the stock as we are skeptical of the added benefits of the
long awaited production facility and the reactivation of its agreement with the government
over Biovaccines. In the interim, we value May & Baker at a forward PE of 11.3x and an
EV/EBITDA of 6.5x translating to a target price of N4.52 thereby placing a NEUTRAL
recommendation on the stock. We note that management has disclosed plans to improve its
marketing and distribution efforts with incursions into new geographical locations and
markets as well as its interests in the Nutraceuticals and insecticide-treated mosquito netmarket segment. We expect this to translate to enhanced earnings and market share in the
near term.
Chart 13: May & Baker Versus Sector and NSE (LTM Price Performance)
Source: Afrinvest Research
Adjusted Prices, Rebased. Jan 04, 2010=100
May & Baker Nigeria Plc
Market Data
Price Range (Low/High) 2.76 - 6.94
Price Performance (YTD, %) 52.3
Share Price (Dec 31, 2010) 4.20
Shares Outstanding (m) 980.0
Market Cap (Nm) 4,116.0
Market Cap (US$m) 27.4
Avg Daily Value (Nm) 3.8
Avg Daily Value (US$ '000) 0.03
Avg Daily Vol (Nm) 0.6
Company Data
Year Ended, June 30 2009 2010F
Sales (Nm) 4,604.5 4,696.5
Profit After Tax (Nm) 232.1 699.5
Earnings per Share (Kobo)* 0.27 0.71
Dividend per Share (Kobo) - -
Sales Growth (%) -15.4 2.0
PAT Growth (%) -44.5 201.4
ROE (%) 8.6 19.7
Dividend Yield (%) - -
17
Valuations
EV/Sales (x) 1.0
EV/EBIT (x) 9.8
EV/EBITDA (x) 6.9
Working Capital/Sales (%) 0.2
Capex/EBITDA (%) 2.2
DCF Value (N) 3.66
Adjusted EPS*
-
8/7/2019 Afrinvest Pharmaceutical & Healthcare Sector Update
19/19
Healthcare/Pharmaceuticals Sector8
This report has been issued and approved by Afrinvest West Africa Limited (Afrinvest). This report is based on information fromvarious sources that we believe are reliable; however, no, representation is made that it is accurate or complete. While reasonable carehas been taken in preparing this document no responsibility or liability is accepted for errors or fact or for any opinion expressed herein.This document is for information purposes only. It does not constitute any offer or solicitation to any person to enter into any tradingtransaction. Any investment discussed may not be suitable for all investors. This report is provided solely for the information of clients ofAfrinvest who are expected to make their own investment decisions. Afrinvest conducts designated investment business with marketcounter parties and intermediate customers and this document is directed only at such persons. Other persons should not rely on this
document. Afrinvest accepts no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.This report is for private circulation only. This report may not be reproduced distributed or published by any recipient for any purposewithout prior express consent of Afrinvest. Investments can fluctuate in price and value and the investor might get back less than wasoriginally invested. Past performance is not necessarily a guide to future performance. It may be difficult for the investor to realize aninvestment. Afrinvest and/or a connected company may have a position in any of the instruments mentioned in this document. Afrinvestand/or a connected company may or may not have in the future a relationship with any of the entities mentioned in this document forwhich it has received or may receive in the future fees or other compensation. Afrinvest is a member of The Nigerian Stock Exchange andis regulated by the Securities and Exchange Commission to conduct investment business in Nigeria.
AFRINVEST LIMITED 27 GERRARD ROAD, IKOYI, LAGOS, NIGERIA. PHONE NO: 2701680 88, 269 5479-81, 269 4005, 269 0861, 29629482670272 3, 2692810.Fax: 2694392, 2701689.
Victor NdukaubaBanking and Infrastructure
[email protected]+234 1 2701680 ext 311
Babatunde ObaniyiBanking and Petroleum [email protected]+234 1 2701680 ext 314
Kayode TinuoyeInsurance
[email protected]+234 1 2701680 ext 317
Oladipo JamesHealthcare/ Chemicals & Paints
[email protected]+234 1 2701680 ext 312
INVESTMENT RESEARCH
IMPORTANT DISCLOSURES AND DISCLAIMERS
CONTACTS
Afrinvest27, Gerrard Road,Ikoyi,Lagos,Nigeria.
Tel: +234 1 270 1680-8Fax: +234 1 269 4392
www.afrinvest.com